ValuEngine upgraded shares of Assembly Biosciences (NASDAQ:ASMB) from a hold rating to a buy rating in a research report released on Wednesday, ValuEngine reports.

A number of other research firms also recently commented on ASMB. BidaskClub downgraded Assembly Biosciences from a buy rating to a hold rating in a report on Thursday, January 2nd. William Blair reissued a buy rating on shares of Assembly Biosciences in a research note on Thursday, November 7th. Robert W. Baird set a $74.00 price objective on shares of Assembly Biosciences and gave the company a buy rating in a research note on Thursday, October 17th. Mizuho began coverage on shares of Assembly Biosciences in a research note on Tuesday, October 15th. They issued a buy rating and a $20.00 price objective on the stock. Finally, Zacks Investment Research cut shares of Assembly Biosciences from a buy rating to a hold rating in a research note on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Assembly Biosciences has an average rating of Buy and an average target price of $36.75.

Assembly Biosciences stock traded down $0.38 during trading hours on Wednesday, hitting $17.75. The stock had a trading volume of 8,329 shares, compared to its average volume of 347,008. The company has a debt-to-equity ratio of 0.06, a current ratio of 7.69 and a quick ratio of 7.69. Assembly Biosciences has a 1-year low of $8.13 and a 1-year high of $25.07. The stock’s fifty day moving average is $19.34 and its two-hundred day moving average is $14.52. The stock has a market capitalization of $482.65 million, a price-to-earnings ratio of -4.45 and a beta of 1.60.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.03). Assembly Biosciences had a negative return on equity of 52.83% and a negative net margin of 647.72%. The firm had revenue of $4.23 million during the quarter, compared to analysts’ expectations of $3.45 million. As a group, sell-side analysts anticipate that Assembly Biosciences will post -3.57 EPS for the current year.

In other Assembly Biosciences news, EVP Richard James Colonno sold 33,061 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $25.00, for a total transaction of $826,525.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Jacqueline Sybil Papkoff sold 1,460 shares of the business’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $21.00, for a total transaction of $30,660.00. Following the sale, the senior vice president now directly owns 22,915 shares in the company, valued at approximately $481,215. The disclosure for this sale can be found here. Company insiders own 12.42% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of Montreal Can lifted its holdings in shares of Assembly Biosciences by 2,084.1% during the second quarter. Bank of Montreal Can now owns 1,922 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 1,834 shares during the period. Tower Research Capital LLC TRC lifted its holdings in Assembly Biosciences by 9,134.0% in the second quarter. Tower Research Capital LLC TRC now owns 4,340 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 4,293 shares during the period. Millennium Management LLC lifted its holdings in Assembly Biosciences by 23.6% in the third quarter. Millennium Management LLC now owns 11,199 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 2,138 shares during the period. Algert Global LLC acquired a new position in Assembly Biosciences in the second quarter valued at $182,000. Finally, Rhumbline Advisers lifted its holdings in Assembly Biosciences by 8.3% in the third quarter. Rhumbline Advisers now owns 34,939 shares of the biopharmaceutical company’s stock valued at $343,000 after buying an additional 2,667 shares during the period. 79.56% of the stock is currently owned by hedge funds and other institutional investors.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

Read More: What are the benefits of a portfolio tracker?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.